High-dose statin therapy does not induce insulin resistance in patients with familial hypercholesterolemia

Metabolic Syndrome and Related Disorders

Volumn 10, Issue 5, 2012, Pages 351-357

  Panz, Vanessa ^a   Immelman, Andrew ^a   Paiker, Janice ^a   Pilcher, Gillian ^a   Raal, Frederick ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ATORVASTATIN; C REACTIVE PROTEIN; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROINSULIN; ROSUVASTATIN; SIMVASTATIN;

ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CALCULATION; CORONARY ARTERY DISEASE; CORRELATIONAL STUDY; DIET RESTRICTION; DISEASE MARKER; DRUG MEGADOSE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HETEROZYGOSITY; HOMEOSTASIS; HOMOZYGOSITY; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL;

ADIPONECTIN; ADOLESCENT; ADULT; CAROTID INTIMA-MEDIA THICKNESS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84872874440     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2012.0063     Document Type: Article

References (43)

1. Goldstein JL, Hobb HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 8th ed. New York, NY: McGraw-Hill; 2001: 2863-2913.
2. Reaven GM. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med 2005;47: 201-210.
3. PyöräläM, Miettinen H, Laakso M, et al. Plasma insulin and all-cause, cardiovascular, and nonvascular mortality: the 22-year follow-up results of the Helsinki Policemen Study. Diabetes Care 2000;8:1097-1102.
4. Hu G, Qiao Q, Tuomilehto J, et al.; DECODE Insulin Study Group. Plasma insulin and cardiovascular mortality in nondiabetic European men and women: A meta-analysis of data from eleven prospective studies. Diabetologia 2004;47:1245-1256.
5. Agewall S, Fagerberg B, Attval S, et al. Carotid artery wall intima-media thickness is associated with insulin-mediated glucose disposal in men at high and low coronary risk. Stroke 1995;26:956-960.
6. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-194.
7. Das UN. Is obesity an inflammatory condition? Nutrition 2001;17:953-966.
8. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005;115:911-919.
9. Hansson GK. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 2005;352:1685-1695.
10. Theuma P, Fonseca VA. Inflammation, insulin resistance, and atherosclerosis. Metab Synd Relat Disord 2004;2:105-113.
11. Patel JV, Abraheem A, Dotsenko O, et al. Circulating serum adiponectin levels in patients with coronary artery disease: Relationship to atherosclerotic burden and cardiac function. J Intern Med 2008;264:593-598.
12. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257:79-83.
13. Hara K, Yamauchi T, Imai Y, et al. Reduced adiponectin level is associated with severity of coronary artery disease. Int Heart 2007;48:149-153.
14. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;5:1930-1935.
15. Raal FJ, Panz VR, Pilcher GJ, et al. Atherosclerosis seems not to be associated with hyperinsulinaemia in patients with familial hypercholesterolaemia. J Int Med 1999;249:75-80.
16. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
17. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: Insulin resistance and B-cell function from fasting glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
18. Veller MG, Fisler CM, Nicolaides AN, et al. Measurement of the ultrasonic intima-media complex thickness in normal subjects. J Vasc Surg 1993;4:719-725.
19. Reaven G, Abbasi F, McLaughlin T. Obesity, insulin resistance, and cardiovascular disease. Recent Prog Horm Res 2004;59:207-223.
20. Zeyda M, Stulnig TM. Obesity, inflammation, and insulin resistance-a min-review. Gerontology 2009;55:379-386.
21. Reaven GM. Insulin resistance: The link between obesity and cardiovascular disease. Med Clin North Am 2011;95:875-892.
22. Galvan AQ, Santoro D, Natali A, et al. Insulin sensitivity in familial hypercholesterolemia. Metabolism 1993;42:1359-1364.
23. KarhapääP, Voutilainen E, Kovanen PT, et al. Insulin resistance in familial and nonfamilial hypercholesterolemia. Arterioscler Thromb 1993;13:41-47.
24. Brooks GC, Blaha MJ, Blumenthal RS. Relation of C-reactive protein to abdominal obesity. Am J Cardiol 2010;106:56-61.
25. Khaodhiar L, Ling PR, Blackburn GL, et al. Serum levels of interleukin-6 and C-reactive protein correlate with body mass index across the broad range of obesity. J Parenter Enteral Nutr 2004;28:410-415.
26. Guldiken S, Demir M, Arikan E, et al. The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: Soluble CD40 ligand and high-sensitivity C-reactive protein. Thromb Res 2007:119:79-84.
27. Kinlay S. Low-density lipoprotein-dependent and-independent effects of cholesterol-lowering therapies on Creactive protein: a meta-analysis. J Am Coll Cardiol 2007;49: 2003-2009.
28. Preiss D, Sattar N. Statins and the risk of new-onset diabetes: A review of recent evidence. Curr Opin Lipidol 2011;22: 460-466.
29. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012; DOI: 10.1001/archinternmed. 2011.625.
30. Koh KK, Sakuma I, Quon MJ. Differential metabolic effects of distinct statins. Atherosclerosis 2011;215:1-8.
31. Ridker PM, Danielson E, Fonseca FA, et al.; JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet 2009;373:1175-1182.
32. Raal FJ, Pilcher GJ, Illingworth DR, et al. Expanded-dose simvastatin in homozygous familial hypercholesterolemia. Atherosclerosis 1997;135:244-256.
33. Raal FJ, Pappu AS, Illingworth DR, et al. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolemia. Atherosclerosis 2000;150:421-428.
34. Marais AD, Raal FJ, Stein EA, et al. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolemia. Atherosclerosis 2008;197:400-406.
35. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolemia: A long term cohort study. BMJ 2008;337:a2423.
36. Laasko M, Sarlund H, Mykkänen L. Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arteriosclerosis 1990;10:223-231.
37. Reaven GH. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
38. Steffes MW, Gross MD, Schreiner PJ, et al. Serum adiponectin in young adults-interactions with central obesity, circulating levels of glucose, and insulin resistance: The CARDIA study. Ann Epidemiol 2004;14:492-498.
39. Nawrocki AR, Hofmann SM, Teupser D, et al. Lack of association between adiponectin levels and atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2010;30:1159-1165.
40. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol Endocrinol Metab 1979;237:E214-E223.
41. Straczkowski M, Stepien A, Kowalska I, et al. Comparison of simple indices of insulin sensitivity using the euglycemic hyperinsulinemic clamp technique. Med Sci Monit 2004;10: 480-484.
42. Malita FM, Karelis AD, St-Pierre DH, et al. Surrogate indices vs. euglycemic-hyperinsulinemic clamp as an indicator of insulin resistance and cardiovascular risk factors in overweight and obese postmenopausal women. Diabetes Metab 2006;32:251-255.
43. Ntyintyane L, Panz V, Raal F, et al. Comparison between surrogate indices of insulin sensitivity and resistance, and the hyperinsulinaemic euglycaemic glucose clamp in urban South African blacks with and without coronary artery disease. Diab Vasc Dis Res 2010;7:151-157.